BREAKING
AbCellera Biologics Inc (ABCL) reported Q4 2025 earnings per share of $-0.19, missing the consensus estimate of $-0.16 by 17.3%.
Revenue totaled $35.3M for the Q4 2025 period.
Shares fell 2.3% in after-hours trading to $3.00.
The 17.3% earnings miss represents a notable shortfall versus analyst expectations.
Full analysis with detailed breakdown coming shortly on AlphaStreet.